9 hours Ago By ABMN Staff
AlphaQuest LLC acquired a new stake in Kura Oncology, Inc. ( NASDAQ:KURA – Free Report ) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 20,331 shares of the company’s stock, valued at approximately $177,000.
Other institutional investors have also made changes to their positions in the company. China Universal Asset Management Co. Ltd.
increased its position in Kura Oncology by 11.9% in the 4th quarter. China Universal Asset Management Co.
Ltd. now owns 16,489 shares of the company’s stock worth $144,000 after buying an additional 1,750 shares during the period. Rhumbline Advisers increased its position in Kura Oncology by 2.
0% in the 4th quarter. Rhumbline Advisers now owns 99,991 shares of the company’s stock worth $871,000 after buying an additional 1,923 shares during the period. Harbor Capital Advisors Inc.
increased its position in Kura Oncology by 4.4% in the 4th quarter. Harbor Capital Advisors Inc.
now owns 49,371 shares of the company’s stock worth $430,000 after buying an additional 2,076 shares during the period. JPMorgan Chase & Co. increased its position in Kura Oncology by 0.
8% in the 3rd quarter. JPMorgan Chase & Co. now owns 409,241 shares of the company’s stock worth $7,997,000 after buying an additional 3,092 shares during the period.
Finally, Bellevue Group AG increased its position in shares of Kura Oncology by 36.0% during the third quarter. Bellevue Group AG now owns 13,600 shares of the company’s stock valued at $266,000 after purchasing an additional 3,600 shares during the period.
Wall Street Analyst Weigh In A number of analysts have recently issued reports on the company. TD Cowen restated a “buy” rating on shares of Kura Oncology in a research report on Thursday, November 21st. Wedbush restated an “outperform” rating and set a $36.
00 price objective on shares of Kura Oncology in a research report on Thursday, February 27th. UBS Group lowered their price objective on Kura Oncology from $27.00 to $14.
00 and set a “buy” rating on the stock in a research report on Thursday, March 6th. Jefferies Financial Group lowered their price objective on Kura Oncology from $32.00 to $28.
00 and set a “buy” rating on the stock in a research report on Thursday, November 21st. Finally, StockNews.com upgraded Kura Oncology from a “hold” rating to a “buy” rating in a research report on Friday, March 7th.
Three investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Kura Oncology presently has an average rating of “Moderate Buy” and an average price target of $25.50.
Insiders Place Their Bets In other Kura Oncology news, SVP Thomas James Doyle sold 4,949 shares of the business’s stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.
63. Following the transaction, the senior vice president now owns 88,193 shares of the company’s stock, valued at approximately $694,078.91.
The trade was a 5.31 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink .
Also, insider Mollie Leoni sold 4,963 shares of the business’s stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $39,058.
81. Following the completion of the transaction, the insider now directly owns 88,253 shares in the company, valued at approximately $694,551.11.
This represents a 5.32 % decrease in their position. The disclosure for this sale can be found here .
Over the last quarter, insiders have sold 11,729 shares of company stock valued at $92,307. 5.50% of the stock is currently owned by corporate insiders.
Kura Oncology Price Performance Shares of KURA stock opened at $7.14 on Monday. The stock’s fifty day simple moving average is $7.
86 and its 200 day simple moving average is $12.84. The company has a debt-to-equity ratio of 0.
02, a current ratio of 11.47 and a quick ratio of 11.47.
The firm has a market cap of $576.59 million, a price-to-earnings ratio of -3.03 and a beta of 0.
85. Kura Oncology, Inc. has a one year low of $6.
79 and a one year high of $23.48. Kura Oncology ( NASDAQ:KURA – Get Free Report ) last posted its quarterly earnings data on Wednesday, February 26th.
The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.
43. The business had revenue of $53.88 million during the quarter, compared to analyst estimates of $57.
96 million. On average, analysts expect that Kura Oncology, Inc. will post -2.
44 earnings per share for the current fiscal year. Kura Oncology Profile ( Free Report ) Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer.
Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. Recommended Stories Want to see what other hedge funds are holding KURA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kura Oncology, Inc.
( NASDAQ:KURA – Free Report ). Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter .
.
